Moberg Pharma AB (publ) MOB
Updated: 9 Aug 2026
No signal published yet
We already track Moberg Pharma and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Moberg Pharma AB (publ)? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Moberg Pharma free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On May 12, 2026, Moberg Pharma published its Q1 2026 interim report, reporting net revenue of SEK 4.9 million and cash and cash equivalents of SEK 222.5 million. During the period, the company expanded its licensing collaboration with Karo Healthcare to cover additional markets in Asia-Pacific. The company also secured regulatory approval for an additional supplier of terbinafine.
What Firelda Watch includes for Moberg Pharma AB (publ)
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Moberg Pharma AB (publ)? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Moberg Pharma free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more